Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients

ClinicalTrials.gov ID: NCT00001038

Public ClinicalTrials.gov record NCT00001038. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients With Advanced HIV Infection (< 100 CD4+ Lymphocytes)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

PRIMARY: To evaluate the efficacy of valacyclovir hydrochloride (BW 256U87) in the prevention of cytomegalovirus (CMV) end-organ disease in HIV/CMV co-infected patients with CD4+ lymphocytes \< 100 cells/mm3. To assess the impact of BW 256U87, high-dose oral acyclovir and low-dose oral acyclovir on survival. SECONDARY: To evaluate the effect of BW 256U87 on quality of life, the safety of the drug administered concurrently with standard antiretroviral agents and other essential therapies for the treatment and prevention of opportunistic diseases, and the efficacy of BW 256U87 in suppressing activation of other herpesviruses. To evaluate serologic and virologic risk factors for the development of CMV disease, including assessment of HIV activation, and the risk of developing drug-resistant CMV, HSV, and VZV. Gastrointestinal absorption of acyclovir is not high enough to prevent CMV disease in patients with advanced HIV disease, although there is evidence that high doses of the drug may extend survival. Valacyclovir, a prodrug that is rapidly converted to acyclovir after oral administration, has a higher absorption rate and may therefore provide inhibitory activity against CMV.

Study identification

NCT ID
NCT00001038
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
1,200 participants

Conditions and interventions

Eligibility (public fields only)

Age range
13 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Not listed
Primary completion
Apr 30, 1996
Completion
Not listed
Last update posted
Feb 28, 2011

United States locations

U.S. sites
21
U.S. states
15
U.S. cities
19
Facility City State ZIP Site status
Birmingham Veterans Administration Med Ctr Birmingham Alabama 35233
Los Angeles County - USC Med Ctr Los Angeles California 90033
CARE Ctr / UCLA Med Ctr Los Angeles California 900951793
Highland Gen Hosp / San Francisco Gen Hosp Oakland California 946021018
Univ of California / San Diego Treatment Ctr San Diego California 921036325
Kaiser Permanente Med Ctr San Francisco California 94115
Univ of Colorado Health Sciences Ctr Denver Colorado 80262
Yale Univ New Haven Connecticut 06519
Northwestern Univ Med School Chicago Illinois 60611
Indiana Univ Hosp Indianapolis Indiana 462025250
Johns Hopkins Hosp Baltimore Maryland 212052196
Harvard (Massachusetts Gen Hosp) Boston Massachusetts 02114
Boston Med Ctr Boston Massachusetts 02118
Washington Univ St Louis Missouri 63110
Mount Sinai Med Ctr New York New York 10029
North Central Bronx Hosp / Bronx Municipal Hosp The Bronx New York 10467
Univ of North Carolina School of Medicine Chapel Hill North Carolina 275997215
Ohio State Univ Hosp Clinic Columbus Ohio 432101228
Girard Med Ctr Philadelphia Pennsylvania 191046073
Univ TX Galveston Med Branch Galveston Texas 775550882
Univ of Washington / Madison Clinic Seattle Washington 98122

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00001038, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 28, 2011 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00001038 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →